Quidel
| Quidel Corporation | |
|---|---|
| legal form | Corporation |
| founding | 1979 |
| Seat | San Diego , California |
| management | Douglas C. Bryant, President and Chief Executive Officer |
| Number of employees | 1224 (2018) |
| sales | $ 534.9 million |
| Branch | Pharmaceutical manufacturer |
| Website | www.quidel.com |
| As of May 10, 2020 | |
Quidel is an American manufacturer of diagnostics that can be used to diagnose infectious diseases as well as cardiovascular and metabolic diseases. It was founded in 1979, has been listed on the American technology exchange NASDAQ since 1991 under the QDEL label and is headquartered in San Diego , California .
In May 2020, the Food and Drug Administration (FDA) issued the first emergency approval (EUA) for a COVID-19 antigen test . This is a completely new category of tests for use in the ongoing corona pandemic . These diagnostic tests quickly detect fragments of proteins found on or in the virus by testing samples taken from swabs from the nasal cavity.
Corporate background
Quidel started operations in 1979 and launched its first products in 1983 and the world's first rapid diagnostic test for influenza A / B in 1999. Since then, Quidel has seen double-digit growth and expanded its market reach through in-house product development and acquisitions. The focus was on investing in research and development to accelerate the pace of new product launches.
In 2010, Quidel acquired Athens Diagnostic Hybrids, Inc., a leading provider of cell culture-based diagnostic tests sold direct to end users. In 2011, Quidel acquired BioHelix, Inc., a manufacturer and developer of molecular diagnostic products, including BioHelix's proprietary HDA isothermal molecular amplification technology. In December 2014, Quidel raised $ 172.5 million through a convertible bond issue (3.25% coupon, due 2020). Quidel's largest acquisition came in October 2017 through the acquisition of Alere's Triage and Beckman BNP Businesses, effectively doubling the size of the company in terms of sales and employees, reducing seasonal flu sales volatility, and significantly expanding Quidel's international footprint.
Quidel's core competencies include the development of instrumented immunoassays , automated manufacturing in the USA, the characterization and development of monoclonal antibodies, and the development of molecular assays.
Products
Quidel's current products fall into these categories:
- Cardiac immunoassay,
- Rapid immunoassay, where Quidel is the market leader in infectious disease testing,
- Special diagnostic solutions
- and the molecular diagnostics business.
Web links
Individual evidence
- ↑ Executive Management , Company Website, accessed May 10, 2020
- ↑ a b Investor FAQs , Company Website, accessed May 10, 2020
- ↑ Quidel Reports Fourth Quarter and Full Year 2019 Financial Results , Quidel PM, February 12, 2020, accessed May 10, 2020
- ↑ Coronavirus (COVID-19) Update: FDA Authorizes First Antigen Test to Help in the Rapid Detection of the Virus that Causes COVID-19 in Patients , PM FDA of May 9, 2020, accessed May 10, 2020
- ↑ Completely new corona test approved in the USA , SPON from May 10, 2020, accessed on May 10, 2020
- ^ Corporate Profile , Company Website, accessed May 10, 2020